Kymera Investor Presentation Deck

● ● ● ● KT-474 Phase 1 Data Supports Phase 2 Advancement Healthy Volunteers (HV), SAD and MAD Evaluated safety, tolerability and pharmacokinetics in 132 healthy volunteers SAD: oral doses of 25-1600 mg MAD: escalating doses up to 200 mg were administered for 14 consecutive days Robust ( >95%) and sustained IRAK4 degradation with single and multiple daily doses Broad inhibition of ex vivo TLR-mediated cytokine induction Generally well-tolerated across all dose groups KYMERA ©2023 KYMERA THERAPEUTICS, INC. ● ● ● ● HS and AD Patient Cohort Open label study in 21 patients with HS and AD Dose: 75 mg QD with food (equivalent exposure to 100 mg fasted), administered for 28 consecutive days Safety, PK and PD comparable to healthy volunteers Robust IRAK4 degradation in blood and skin with associated systemic anti-inflammatory effect in HS and AD patients Promising clinical activity observed in HS and AD PAGE 10

View entire presentation